Abstract. The imbalance induced by inhibition of bone mesenchymal stem cell (BMSC) osteogenic differentiation results in osteoporosis (OP); however, the underlying regulatory mechanism is not completely understood. Long non-coding RNAs (lncRNAs) serve crucial roles in osteogenic differentiation; therefore, investigating their regulatory role in the process of osteogenic differentiation may identify a promising therapeutic target for OP. The expression of small nucleolar RNA host gene 1 (SnHG1), dickkopf 1 (DKK1), microRNA (miR)-101, RUNX family transcription factor 2 (RUNX2), osteopontin (OPN) and osteocalcin (OCN) were detected via reverse transcription-quantitative PCR. The protein expression levels of DKK1, β-catenin, RUNX2, OPN, OCN, osterix and collagen type I α1 chain were analyzed by performing western blotting. The osteoblastic phenotype was assessed by conducting alkaline phosphatase activity detection and alizarin red staining. The interaction between SnHG1 and miR-101 was validated by bioinformatics and luciferase assays. The regulatory role of SnHG1 in BMSc osteogenic differentiation was assessed. SnHG1 expression was downregulated in a time-dependent manner during the process of osteogenic differentiation. SnHG1 overexpression inhibited osteogenic differentiation compared with the pcDNA group. The results indicated that SnHG1 and DKK1 directly interacted with miR-101. Moreover, SnHG1 regulated the Wnt/β-catenin signaling pathway to inhibit osteogenic differentiation via the miR-101/DKK1 axis. The present study indicated that lncRNA SnHG1 could attenuate BMSC osteogenic differentiation via the miR-101/DKK1 axis as a competitive endogenous RNA. Therefore, the present study furthered the current understanding of the potential mechanism underlying lncRNAs in osteogenic differentiation.

Introduction

As a serious chronic systemic bone disease, osteoporosis (OP) involves excessive bone resorption and decreased bone formation (1), resulting from an imbalance induced by inhibition of osteogenic differentiation (2), such as abnormal bone mesenchymal stem cell (BMSC) differentiation, the precursor cells of osteoblasts (2). Due to their osteogenic differentiation ability, BMSCs were indicated to be a suitable cell type for the repair and remodeling of bones (3). Therefore, it is of significance to induce BMSC differentiation into bone tissues for OP treatment, and the mechanism to enhance osteogenic differentiation has received increasing attention.

Long non-coding RNAs (lncRNAs) are non-coding RNAs, >200 nucleotides in length, that regulate different processes via various molecular mechanisms (4). It has been reported that lncRNAs participate in regulating osteogenic activity. For instance, KCNQ1 opposite strand/antisense transcript 1 (KCNQ1OT1) regulates osteogenic differentiation by sponging microRNA (miRNA/miR)-214 (5), whereas MALAT1 promotes osterix (OSX) expression to regulate osteogenic differentiation by sponging miRNA-143 (6). Small nucleolar RNA host gene 1 (SNHG1) is upregulated in numerous types of cancer (7,8), and can attenuate heterogeneous nuclear ribonucleoprotein C-p53 protein interactions to enhance the stability of p53 (4). Besides, elevated SNHG1 can contribute to the progression of non-small cell lung cancer via inhibition of miR-101-3p (9). Moreover, SNHG1 inhibits BMSC osteogenic differentiation by modulating the p38 MAPK signaling pathway (10). However, the molecular mechanism underlying lncRNA SNHG1-mediated regulation of BMSC differentiation is not completely understood.

miRNAs are 18-25 base-long endogenous RNAs that are involved in regulating multiple physiological biological processes (11). miR-101 is significantly upregulated during human BMSC osteogenic differentiation, and it can target the enhancer of zeste 2 polycomb repressive complex 2
sublation/Wnt/β-catenin signaling pathway to promote human BMSC osteogenic differentiation (12). Bioinformatics analysis has revealed that SNHG1 has a miR-101 binding region (13); however, whether SNHG1 regulates BMSC osteogenic differentiation by binding with miR-101 is not completely understood.

The entire osteoblastic lineage is affected by Wnt signaling, and Wnt/β-catenin signaling can indirectly repress osteoclast differentiation and bone resorption (14,15). Dickkopf 1 (DKK1) is a Wnt signaling inhibitor, which inhibits the canonical Wnt signaling pathway by binding to the Wnt complex receptor Low-density lipoprotein receptor-related protein 5/6 (16). By bioinformatics, it was also predicted that there may be a binding site between miR-101 and DKK1 (17). Moreover, to the best of our knowledge, no previous study has focused on the regulation of BMSC osteogenic differentiation via the miR-101/DKK1/Wnt axis. It was hypothesized that the SNHG1/miR-101/DKK1 axis served a regulatory role in BMSC osteogenic differentiation.

Materials and methods

Cell culture. Human BMSCs (cat. no. HUXMA-01001; Cyagen Biosciences) were cultured in DMEM (HyClone; Cytiva) containing 10% FBS (Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 U/ml streptomycin. Cells were cultured in a humidified atmosphere containing 5% CO₂ at 37°C.

Induction of osteogenic differentiation. To induce osteogenic differentiation, cells were cultured in osteogenic differentiation medium consisting of dMeM with 10% FBS, dexamethasone (100 nM; Sigma-Aldrich; Merck KGaA), ascorbic acid 2-phosphate (200 µM; Sigma-Aldrich; Merck KGaA) and β-glycerophosphate (10 mM; Sigma-Aldrich; Merck KGaA) for 15 days at 37°C. The medium was changed every 3 days.

Cell transfection. pcDNA-SNHG1 and miR-101 mimics were constructed and purchased from Shanghai GenePharma Co., Ltd.. Cells were transfected with 200 ng/well pcDNA-SNHG1, pcDNA empty vector and 50 nM miR-101 mimics (UAC AGUACUGUAUAACUGAA) and its scramble control (mimics-NC) (UCACACCUCCUCAAGAAGA) using Lipofectamine® 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocol when the confluency of the cells reached 70-80%. Then, cells were collected at 48 h after transfection for further use.

Luciferase activity assay. The predicted miR-101 binding site in SNHG1 and DKK1, as well as the mutated regions, were amplified and cloned into the pmirGLO plasmid (Promega Corporation). Then, 1×10⁵/well 293T cells were co-transfected with 800 ng luciferase reporter plasmid and 50 pmol miRNA mimics or mimics-negative control (NC) using Lipofectamine 3000 in a 24-well plate. At 48 h post-transfection, the Dual-Luciferase Reporter Assay system (Promega Corporation) was used to examine relative luciferase activity. Fluorescence signals were normalized to those of Renilla luciferase activity, and are presented as the mean ± SD of three independent experiments.

Alkaline phosphatase (ALP) activity detection. ALP staining was performed using an ALP activity colorimetric assay kit (BioVision, Inc.) following the manufacturer’s instructions. Briefly, cells were fixed with 70% ethanol at room temperature for 30 min and washed with PBST. Then, 50 µl 5 mM P-nitrophenyl phosphate (p-NP) solution was added to test and control samples, and 10 µl ALP enzyme solution was added to each p-NP Standard wells and incubated at room temperature for 15-30 min. Cells were gently washed three times with cold PBS. Subsequently, cells were lysed with 1% Triton X-100 (Sigma-Aldrich; Merck KGaA) and washed with deionized water. The absorbance of p-nitrophenol at a wavelength of 405 nm was measured using a microplate reader (Bio-Rad Laboratories, Inc.) according to the manufacturer’s instructions.

Alizarin red staining (ARS). ARS (Cyagen Biosciences, Inc.) was conducted to assess mineral deposition. Briefly, cells were fixed with 4% paraformaldehyde at room temperature for 15 min and stained with 2% Alizarin Red S (pH 4.2; Sigma-Aldrich; Merck KGaA) at room temperature in deionized water for 20 min. Subsequently, cells were washed with PBS and observed under a light microscope (Leica Microsystems GmbH, magnification, x100).

Reverse transcription-quantitative PCR (RT-qPCR). Total RNA was extracted from cells using TRIzol® (Invitrogen; Thermo Fisher Scientific, Inc.). Total RNA was reverse transcribed into cDNA using the iPROM-II Reverse Transcription system (Promega Corporation) following the manufacturer’s instructions. Briefly, the reaction was incubated at 37°C for 1 h followed by 95°C for 5 min and 4°C for 5 min. Subsequently, qPCR was performed on days 0, 7 and 15 of osteogenic differentiation using TransStart Eco Green qPCR SuperMix (TransGen Biotech Co., Ltd.) and the following thermocycling conditions: Initial denaturation at 95°C for 10 min; 40 cycles of denaturation/annealing/extension at 95°C for 15 sec; 60°C for 30 sec and followed by final extension at 60°C for 30 sec. The following primer sequences were used for qPCR: SNHG1 forward, 5’-ACTTCCACTTTGTTGCTGTTCC-3’ and reverse, 5’-TGAAGAGCAAGCCCTGGAAT-3’; miR-101 forward, 5’-GGCCCGCATACGACTTGTA-3’ and reverse, 5’-GTCGTATCCAGTGCGGTCCAGGTA TCCGACTTGATACGCTTTCA-3’; DKK1 forward, 5’-TGCCCAGGAGAACATTCTGCAAA-3’ and reverse, 5’-CTG GAATTACCATCAGGCTGT-3’; RUNX family transcription factor 2 (RUNX2) forward, 5’-CGAATGCTCTG CTGTTAT-3’ and reverse, 5’-TTCCCGAGGTCACATCTAC TG-3’; osteopontin (OPN) forward, 5’-GATGGGGCGAGGTGATAGTGT-3’ and reverse, 5’-GTGGTTTTCAGACACTCTGTG-3’; osteocalcin (OCN) forward, 5’-GGCCGCGAGAGGTAGAGG-3’ and reverse, 5’-CTGTAACAGGGCGGTAAAG-3’; GAPDH forward, 5’-CACAGTTGCTCTCTCTCTAGA-3’ and reverse, 5’-GTCTGAGCAATATCTGTG-3’; and U6 forward, 5’-CTCGCTTCGGCAGCACA-3’ and reverse, 5’-AACGCT TACAGATTTGCGT-3’. miRNA and mRNA expression levels were quantitated using 2⁻ΔΔCq method and normalized to the internal reference genes U6 and GAPDH, respectively (18).

Western blotting. Total protein was extracted from cells using RIPA lysis buffer containing protease (Beyotime Institute of
Biotechnology). Total protein was quantified using a BCA protein assay (Thermo Fisher Scientific, Inc.). A total of 100 µg protein/lane was separated via 10% SDS-PAGE and transferred to nitrocellulose membranes. After blocking with TBST buffer containing 5% non-fat milk (Thermo Fisher Scientific, Inc.) for 1 h at room temperature, the membranes were incubated with specific primary antibodies at 4°C overnight targeted against: DKK1 (1:1,000; cat. no. ab109416, Abcam), β-catenin (1:1,000; cat. no. ab184919; Abcam), RUNX2 (1:1,000; cat. no. ab192256; Abcam), OCN (1:1,000; cat. no. ab133612; Abcam), OPN (1:1,000; cat. no. ab214050; Abcam), OSX (1:500; cat. no. ab209484; Abcam), collagen type I α1 chain (1:1,000; cat. no. ab34710; Abcam), and β-actin (1:1,000; cat. no. ab8226; Abcam). The membranes were then incubated with secondary antibodies conjugated to horseradish peroxidase at a 1:1,000 dilution for 1 h at room temperature. Protein expression levels were quantified by densitometry using ImageJ software. The relative expression levels of DKK1, RUNX2, OPN, and OCN were calculated relative to β-actin. *P<0.05, **P<0.01 and ***P<0.001. SNHG1, small nucleolar RNA host gene 1; DKK1, dickkopf Wnt signaling pathway inhibitor 1; miR, microRNA; RUNX2, RUNX family transcription factor 2; OCN, osteocalcin; OPN, osteopontin; ALP, alkaline phosphatase; BMSC, bone mesenchymal stem cell; d, days.

Figure 1. Expression of SNHG1, DKK1 and miR-101 during osteogenic differentiation. Expression of (A) SNHG1, (B) miR-101, (C) DKK1, (D) RUNX2, (E) OCN and (F) OPN in osteogenic differentiation medium-treated BMSCs at different time points. (G) ALP activity and (H) Alizarin Red staining in osteogenic differentiation medium-treated BMSCs at different time points. Protein expression levels were (I) determined by western blotting and (J) semi-quantified for DKK1, RUNX2, OPN and OCN in osteogenic differentiation medium-treated BMSCs at different time points. *P<0.05, **P<0.01 and ***P<0.001. SNHG1, small nucleolar RNA host gene 1; DKK1, dickkopf Wnt signaling pathway inhibitor 1; miR, microRNA; RUNX2, RUNX family transcription factor 2; OCN, osteocalcin; OPN, osteopontin; ALP, alkaline phosphatase; BMSC, bone mesenchymal stem cell; d, days.
Xiang et al.: SNHG1 attenuates osteogenic differentiation

3718

SnHG1 attenuates osteogenic differentiation. After induction of osteogenic differentiation, the expression of SNHG1, miR-101, DKK1, and osteogenesis-related genes, including RUNX2, OCN, and OPN, on day 0, 7, and 15 were detected via RT-qPCR. During the process of osteogenic differentiation, the expression of miR-101 and the osteogenesis-related genes were upregulated, whereas SNHG1 and DKK1 were downregulated in a time-dependent manner (Fig. 1A-F). Moreover, ALP activity and mineralization assays indicated an osteoblastic phenotype (Fig. 1G and H). Furthermore, the protein expression levels of the osteogenesis-related genes were also upregulated in a time-dependent manner during the process of osteogenic differentiation, whereas DKK1 protein expression levels were downregulated in a time-dependent manner (Fig. 1I and J). Collectively, the results indicated that SNHG1, miR-101, and DKK1 served a regulatory role in osteogenic differentiation.

SNHG1 and DKK1 are targets of miR-101. Firstly, the binding sites of miR-101 on SNHG1 (Fig. 2A) and DKK1 (Fig. 2B) were predicted by bioinformatics analysis. The luciferase assay indicated that miR-101 mimics significantly decreased the luciferase activity of SNHG1-wild-type (WT), but not significantly alter the luciferase activity of SNHG1-mutated (MUT), indicating a direct interaction between SNHG1 and miR-101 (Fig. 2C). Similarly, miR-101 mimics significantly decreased the luciferase activity of DKK1-WT, but not significantly alter the luciferase activity of DKK1-MUT (Fig. 2D). The results demonstrated that SNHG1 and DKK1 were targets of miR-101.

SNHG1 inhibits BMSC osteogenic differentiation. Compared with pcDNA, SNHG1 overexpression significantly increased the expression of SNHG1 and DKK1 (Fig. 3A), but significantly decreased the expression of miR-101 (Fig. 3A). The expression levels of the osteogenesis-related markers were also significantly decreased by SNHG1 overexpression compared with pcDNA (Fig. 3B). Meanwhile, ALP activity and matrix mineralization were both obviously decreased by SNHG1 overexpression compared with pcDNA (Fig. 3C and D). Compared with pcDNA, the protein expression level of DKK1 was significantly increased, whereas the protein expression levels of the osteogenesis-related markers were significantly decreased after SNHG1 overexpression (Fig. 3E and F), which

Figure 2. SNHG1 and DKK1 directly bind to miR-101. Potential miR-101 binding sites in (A) SNHG1 and (B) DKK1 mRNA were predicted by bioinformatics analysis. The effect of miR-101 mimics on the luciferase activity of (C) SNHG1-WT, SNHG1-MUT, (D) DKK1-WT and DKK1-MUT. "P<0.01. SNHG1, small nucleolar RNA host gene 1; DKK1, dickkopf Wnt signaling pathway inhibitor 1; miR, microRNA; WT, wild-type; MUT, mutated; NC, negative control.
indicated that SNHG1 may inhibit osteogenic differentiation by regulating miR-101 and DKK1.

**SNHG1 inhibits BMSC osteogenic differentiation via miR-101.**

To verify DKK1 was the target of miR-101, BMSCs were transfected with miR-101 mimics and mimics-NC. Compared with the mimics-NC group, DKK1 expression was significantly decreased and miR-101 expression was significantly increased in the miR-101 mimics group (Fig. 4A). To assess whether SNHG1 regulated osteogenic differentiation via miR-101, BMSCs were co-transfected with pcDNA-SNHG1 and miR-101 mimics. SNHG1 overexpression significantly increased DKK1 expression compared with the pcDNA group, which was reversed by co-transfection with miR-101 mimics (Fig. 4B). The expression levels of the osteogenesis-related markers were significantly decreased by SNHG1 overexpression compared with the pcDNA group, whereas co-transfection with miR-101 mimics reversed SNHG1 overexpression-induced effects (Fig. 4C). Furthermore, miR-101 mimics also reversed SNHG1 overexpression-mediated effects on ALP activity and matrix mineralization (Fig. 4D and E). Collectively, the results indicated that miR-101 reversed SNHG1 overexpression-mediated inhibition of osteogenic differentiation.

**SNHG1 regulates the Wnt/β-catenin signaling pathway to attenuate osteogenic differentiation.** As DKK1 was identified as a target of miR-101, whether SNHG1 regulated the expression of DKK1 and proteins in its downstream signaling pathway...
was further examined. SNHG1 overexpression upregulated the protein expression levels of DKK1 and downregulated the protein expression levels of β-catenin, RUNX2, OPN, OCN and COL1a1 compared with pcDNA (Fig. 5A and B). miR-101 mimics reversed SNHG1 overexpression-mediated effects on protein expression (Fig. 5A and B), indicating that SNHG1 regulated the expression of DKK1 and its downstream Wnt/β-catenin signaling pathway by sponging miR-101 to attenuate osteogenic differentiation.

Discussion

As a serious and complicated bone disease, OP is associated with a high risk of fracture (19). Previous studies have demonstrated that abnormal BMSC osteogenic differentiation is the leading cause of OP (2,20,21). Therefore, regulation of BMSC osteogenic differentiation is a vital focus in OP pathogenesis research.

lncRNAs can serve a crucial role in the regulation of osteogenic differentiation. For example, lncRNA twist family bHLH transcription factor (TWIST)1 can promote periodontal mesenchymal stem cells from patients with periodontitis (PPDLSC) and periodontal mesenchymal stem cells from healthy microenvironment (HPDLSC) osteogenic differentiation by inhibiting the expression of TWIST (22). IncRNA-OG was reported to promote BMSC osteogenic differentiation under the regulation of heterogeneous nuclear ribonucleoprotein K (23). Moreover, H19 imprinted maternally expressed transcript (H19) can serve as a competing endogenous RNA (ceRNA) to promote osteogenic differentiation via the Wnt/β-catenin signaling pathway (24). Moreover, IncRNA SNHG1 can inhibit BMSC osteogenic differentiation by modulating the p38 MAPK signaling pathway (10). However, the downstream molecular mechanisms underlying the effects of SNHG1 in osteogenic differentiation are not completely understood. The present study indicated that SNHG1 expression was downregulated in a time-dependent manner during osteogenic differentiation, and SNHG1 overexpression inhibited osteogenic differentiation, indicating a negative regulatory role of SNHG1 in BMSC osteogenic differentiation.

cRNA was reported to be a new regulatory molecular mechanism underlying lncRNAs, where IncRNAs function as...
miRNA sponges to upregulate the expression of their targets (25). SnHG1 was also reported to function as a ceRNA and serve a regulatory role with this mechanism. For instance, SnHG1 can regulate programmed cell death 4 expression by sponging miR-195-5p in hepatocellular carcinoma (26). SnHG1 can also antagonize the effect of miR-145a-5p on the downregulation of NuaK family kinase 1 in nasopharyngeal carcinoma cells (27). Besides, SnHG1 can promote osteosarcoma tumorigenesis by sponging mir-326 (28). Therefore, the present study investigated whether SnHG1 regulated osteogenic differentiation as a ceRNA. As miR-101 was predicted to be the target of SnHG1, the expression of miR-101 and its relationship with SnHG1 in BMSC osteogenic differentiation were investigated. Moreover, the results indicated that miR-101 overexpression reversed SnHG1-mediated inhibition of osteogenic differentiation, indicating that SnHG1 served as a ceRNA to regulate osteogenic differentiation by sponging miR-101. To the best of our knowledge, the present study was the first to suggest that SnHG1 regulated BMSC osteogenic differentiation by sponging miR-101 as a ceRNA.

The Wnt/β-catenin signaling pathway was reported to be involved in osteogenic differentiation, which was also the downstream molecular mechanism underlying a number of IncRNAs (29,30). For example, IncRNA H19 could promote rat ectomesenchymal stem cell osteogenic differentiation via the Wnt/β-catenin signaling pathway (24), whereas IncRNA KCNQ1OT1 promoted osteogenic differentiation to relieve osteolysis via Wnt/β-catenin activation (23). In addition, IncRNA-p21 was also reported to promote mesenchymal stem cell osteogenic differentiation in the rat model of osteoporosis via the Wnt/β-catenin signaling pathway (31). The present study indicated that the Wnt/β-catenin signaling pathway was a downstream mechanism of the SnHG1/miR-101 axis for the regulation of osteogenic differentiation, which was consistent with previous reports.

The present study had a number of limitations. The pathogenesis of OP requires further investigation. For instance, an animal model should be applied to validate the molecular mechanism related to the SnHG1/miR-101/DKK1 axis in regulation of BMSC osteogenic differentiation and prove its therapeutic potential. Therefore, the mechanism identified in the present study requires further investigation using in vivo models of OP. In summary, the present study identified a potential downstream molecular mechanism of the SnHG1 axis in regulating osteogenic differentiation, providing potential therapeutic targets for OP.

Acknowledgements

Not applicable.
Funding
The present study was supported by the Hunan Provincial Health and Family Planning Research Program (grant no. C2019121).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
BC and JX conceptualized and designed the study and revised the manuscript. HQF collected and interpreted the data. WJF, ZX and FL analyzed and interpreted the data. FL drafted the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Isenem RA, McEvoy M, Kelly B, Agnew L, Walker FR and Attia J: Is osteoporosis an autoimmune mediated disorder? Bone Rep 7: 121-131, 2017.
2. Pethong J, Sanvoranart T, Nartprayut K, Nimsanor N, Seenprachawong K, Prachayasitikul V and Supokawej A: Osteoporosis: The current status of mesenchymal stem cell-based therapy. Cell Mol Biol Lett 21: 12, 2016.
3. Oryan A, Kamali A, Moghimi A and Baghaban eslaminejad M: Role of mesenchymal stem cells in bone regenerative medicine: What is the evidence? Cells Tissues Organs 204: 59-83, 2017.
4. Shen Y, Liu S, Fan J, Jin Y, Tian B, Zheng X and Fu H: Nuclear retention of the lncRNA SNHG1 by doxorubicin attenuates hnRNP C-p53 protein interactions. EMBO Rep 18: 536-548, 2017.
5. Wang CG, Liao Z, Xiao H, Liu H, Hu YH, Liao QD and Zhong D: LncRNA KCNQ1OT1 promoted BMP2 expression to regulate osteogenic differentiation by sponging miRNA-214. Exp Mol Pathol 107: 77-84, 2019.
6. Gao Y, Xiao F, Wang C, Wang C, Cui P, Zhang X and Chen X: Long noncoding RNA MALAT1 promotes osterix expression to regulate osteogenic differentiation by targeting miRNA-143 in human bone marrow-derived mesenchymal stem cells. J Cell Biochem 119: 6986-6996, 2018.
7. Sun Y, Wei G, Luo H, Wu W, Skogerbo G, Luo J and Chen R: The long noncoding RNA SNHG1 promotes tumor growth through regulating transcription of both local and distal genes. Oncogene 36: 6774-6783, 2017.
8. Xu M, Chen X, Lin K, Zeng K, Liu X, Pan B, Xu X, Xu T, Hu X, Sun L, et al: The long noncoding RNA SNHG1 regulates colorectal cancer cell growth through interactions with EZH2 and miR-154-5p. Mol Cancer 17: 141, 2018.
9. Cui Y, Zhang F, Zhu C, Geng L, Tian T and Liu H: Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway. Oncotarget 8: 17785-17794, 2017.
10. Jiang Y, Wu W, Jiao G, Chen Y and Liu H: LncRNA SNHG1 modulates p38 MAPK pathway through Nedd4 and thus inhibits osteogenic differentiation of bone marrow mesenchymal stem cells. Life Sci 228: 208-214, 2019.
11. Oliveto S, Mancino M, Manfrini N and Biffo S: Role of microRNAs in translation regulation and cancer. World J Biol Chem 8: 45-56, 2017.
12. Wang H, Meng Y, Cui Q, Qin F, Yang H, Chen Y, Cheng Y, Shi J and Guo Y: MiR-101-3p targets the EZH2/β-catenin pathway to promote the osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. Sci Rep 6: 36988, 2016.
13. Deng R, Zhang J and Chen J: lncRNA SNHG1 negatively regulates miRNA-101-3p to enhance the expression of ROCK1 and promote cell proliferation, migration and invasion in osteosarcoma. Int J Mol Med 43: 1157-1166, 2019.
14. Yavropoulou MP and Yovos JG: The role of the Wnt signaling pathway in osteoblast commitment and differentiation. Hormones (Athens) 6: 279-294, 2007.
15. Albers J, Keller J, Banarowsky A, Beil FT, Catala-Lehnen P, Schulze J, Ameling M and Schinke T: Canonical Wnt signaling inhibited osteoclastogenesis independent of osteoprotegerin. J Cell Biol 200: 537-549, 2013.
16. Li Y, Lu W, King TD, Liu CC, Bijur GN and Bu G: Dkk1 stabilizes Wnt co-receptor LRPs: Implication for Wnt ligand-induced LRPs down-regulation. PLoS One 5: e1014, 2010.
17. Mirfazeli ES, Arefian E, Nasr S, Reza zadeh Valojerd R, Kehtari M and Zeynali M: DKK1 expression is suppressed by miR-9 during induced dopaminergic differentiation of human trabecular meshwork mesenchymal stem cells. Neurosci Lett 707: 134-250, 2019.
18. Livak KJ and Schmittgen TD: Analysis of relative gene expression using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
19. Soizen T, Örzsik L and Başaran NC: An overview and management of osteoporosis. Eur J Rheumatol 4: 56-56, 2017.
20. Zhou DA, Zheng HX, Wang CW, Shi D and Li JJ: Influence of glucocorticoids on the osteogenic differentiation of rat bone marrow-derived mesenchymal stem cells. BMC Musculoskeletal Disord 15: 239, 2014.
21. Wang C, Meng H, Wang X, Zhao C, Peng J and Wang Y: Differentiation of bone marrow mesenchymal stem cells in osteoblasts and adipo cytes and its role in treatment of osteoporosis. Med Sci Monit 22: 226-233, 2016.
22. Xu Y, Qin W, Guo D, Liu J, Zhang M and Jin Z: LncRNA-TwiST1 promotes osteogenic differentiation both in PPDLSCs and in HPDLS Cs by inhibiting TwiST1 expression. Biomed Res Int 2019: 8735952, 2019.
23. Tang S, Xie Z, Wang P, Li J, Wang S, Li M, Wu X, Xu H, Cen S, et al: LncRNA-OG promotes the osteogenic differentiation of bone marrow-derived mesenchymal stem cells under the regulation of LncRNA. Stem Cells 37: 270-283, 2019.
24. Gong YY, Peng MY, Yin DQ and Yang YF: Long non-coding RNA H19 promotes the osteogenic differentiation of rat etomesenchymal stem cells via Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci 22: 8805-8813, 2018.
25. Du Z, Sun T, Hacisuleyman E, Fei T, Wang X, Brown M, Rinn JL, Lee MG, Chen Y, Kantoff PW and Liu XS: Integrative analyses reveal a long noncoding RNA-mediated regulatory network in prostate cancer. Nat Commun 7: 10982, 2016.
26. Huang D, Wei Y, Zhu J and Wang F: Long non-coding RNA SNHG1 functions as a competitive endogenous RNA to regulate PDCCD4 expression by sponging miR-195-5p in hepatocellular carcinoma. Gene 714: 143994, 2019.
27. Lan X and Liu X: LncRNA SNHG1 functions as a ceRNA to antagonize the effect of miR-145a-5p on the down-regulation of NUKI in nasopharyngeal carcinoma cell. J Cell Mol Med 23: 2351-2361, 2019.
28. Wang J, Cao L, Wu J and Wang Q: Long non-coding RNA SNHG1 regulates NOBL1 expression by sponging miR-326 and promotes tumorigenesis in osteosarcoma. Int J Oncol 52: 77-88, 2018.
29. Shen J, Zhang CH, Chen ZW, Wang ZX, Yang DC, Zhang FL and Feng KH: LncRNA HOTAIR inhibited osteogenic differentiation of BMSCs by regulating Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci 23: 7232-7246, 2019.
30. Li N, Ma Y, Wang W, Yin CC, Wu W, Sun R, Zhao G, Li S and Wang X: LOC101928834, a novel lncRNA in Wnt/β-catenin signaling pathway, promotes cell proliferation and predicts poor clinical outcome in myelodysplastic syndromes. Clin Sci (Lond) 134: 1279-1293, 2020.
31. Yang K, Tian N, Liu H, Tao XZ, Wang MX and Huang W: LncRNA2p1 promotes osteogenic differentiation of mesenchymal stem cells in the rat model of osteoporosis by the Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci 23: 4303-4309, 2019.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.